Results 111 to 120 of about 1,151,122 (363)

Episode 87: Vegan Cinema with Anat Pick [PDF]

, 2018
In this episode of Knowing Animals I am joined by Anat Pick. Anat is Associate Professor of Film Studies at Queen Mary University of London. We discuss Anat’s book chapter ‘Vegan Cinema’ which will appear in the book 'Thinking Veganism in Literature and ...
O'Sullivan, Siobhan, Pick, Anat
core   +1 more source

Episode 140: Swimming with Sharks with Roslyn Appleby [PDF]

, 2020
In this episode of Knowing Animals I am joined by Dr. Roslyn Appleby. Ros is a Senior Lecturer in Applied Languages and Literature Studies in the Faculty of Arts and Social Sciences at UTS.
O'Sullivan, Siobhan, Appleby, Roslyn
core   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Episodic refinement of episodic skeletal-plan refinement

International Journal of Human-Computer Studies, 1998
This paper describes successive reformulations of skeletal-plan refinement as a problem-solving method. We argue that, whereas ideas derived from planning literature helped to determine the overall structure of the planning systems, domain-derived considerations and architectural framework in which the systems were implemented played important roles in
Samson W. Tu, Mark A. Musen
openaire   +1 more source

Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms.

Archives of General Psychiatry, 2002
BACKGROUND Most disability produced by psychotic illnesses, especially schizophrenia, develops during the prepsychotic period, creating a case for intervention during this period.
P. McGorry, A. Yung, L. Phillips, H. Yuen, S. Francey, E. Cosgrave, D. Germano, J. Bravin, T. McDonald, A. Blair, S. Adlard, H. Jackson   +11 more
semanticscholar   +1 more source

The Heretic Speaks episode 7, September 18, 2014 [PDF]

, 2014
heretic-speaks_ep07_20140917.mp3 | MP3 Format Sound | 00:10:20 | 14.18 MB | 11/28/2018 10:34:16 AM | .mp3 |This episode is a bit heavy on the announcement side of things. It's also about letting go and giving thanks! Rev.
Pond, Gina A., Rev.
core  

White Matter Hyperintensity Burden and Short‐Interval Change Associated With Sleep Apnoea in the UK Biobank

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background and Purpose White matter hyperintensities (WMH) are a core neuroimaging marker of cerebral small vessel disease (CSVD). Sleep apnoea (SA) is a recognized vascular risk factor, but its associations with regional WMH burden, short‐interval WMH change and cognitive performance in population‐based cohorts remain incompletely defined. We
Peng Cheng, Diego Z. Carvalho, Shahid Karim, Anwar Chahal, Virend K. Somers   +4 more
wiley   +1 more source

Varenicline-induced manic episode

Psychiatry and Behavioral Sciences, 2012
Varenicline is a novel antismoking agent that reduces cravings and blocks pleasure of nicotine by serving as a partial agonist to the nicotinic receptor Varenicline has been associated with some important psychiatric adverseeffects for the patients with ...
Omer Gecici, Melike Nebioglu, Mukerrem Guven   +2 more
doaj   +1 more source

White matter tracts in first-episode psychosis: a DTI tractography study of the uncinate fasciculus. [PDF]

, 2008
A model of disconnectivity involving abnormalities in the cortex and connecting white matter pathways may explain the symptoms and cognitive abnormalities of schizophrenia.
Cercignani, M, Barnes, Thomas R.E., Ron, M A, Barnes, Thomas RE, Barnes, T R E, Parker, Geoffrey J M, Barnes, Thomas R E, Joyce, Eileen M, Altmann, Daniel R., Joyce, Eileen M., Ron, Maria A., Barker, Gareth J, Joyce, E M, Cercignani, Mara, Mara Cercignani (4463104), Parker, Geoffrey JM, Parker, G J M, Geoffrey J M Parker (16050170), Barker, Gareth J., Altmann, Daniel R, Barker, G J; id_orcid, Daniel R Altmann (7040552), Gareth J Barker (16050200), Maria A Ron (16050206), Eileen M Joyce (16050203), Thomas R E Barnes (16050197), Altmann, D R, Ron, Maria A, Gary Price (6445520), Price, G, Parker, Geoffrey J.M., Price, Gary   +31 more
core   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source